Report Store mobile icon
Global Orally Disintegrating Tablet Excipient Market Growth 2024-2030
Global Orally Disintegrating Tablet Excipient Market Growth 2024-2030

2024

Global Orally Disintegrating Tablet Excipient Market Growth 2024-2030

Orally Disintegrating Tablet Excipient market rises from US$16.29 billion in 2023 to US$20.91 billion by 2030, with a 3.6% CAGR, due to increasing demand.

Buy Now Get Free sample

New Report Guarantee

If you purchase this report now and we update it in new 100 days, get it free!

Introduction An orally disintegrating tablet or orally dissolving tablet (ODT) is a drug dosage form available for a limited range of over the counter (OTC) and prescription medications. An excipient is a pharmacologically inert adhesive substance used to bind the contents of a pill or tablet. This type of tablet separates in the mouth in contact with saliva, making it easy for a person to swallow the tablet without drinking water. Market Insights According to Publisher’s latest study, the global Orally Disintegrating Tablet Excipient market size was valued at US$ 16290 million in 2023. With growing demand in downstream market, the Orally Disintegrating Tablet Excipient is forecast to a readjusted size of US$ 20910 million by 2030 with a CAGR of 3.6% during review period.

What's Inside a Bonafide Research`s industry report?

Asia-Pacific dominates the market and is the largest and fastest-growing market in the animal growth promoters industry globally

Download Sample

McePharma (Vivesa holding) was the global greatest company in Orally Disintegrating Tablet Excipient industry, with the revenue market Share of 3% , followed by BASF, JRS Pharma, Roquette, ABF Ingredients, DFE Pharma, Evonik, Merck KGaA, Ashland, Meggle Pharma, Shin-Etsu, Fuji Chemical Industries, Cargill Incorporated, Daicel Corporation, Anhui Sunhere Pharmaceutical. PAC is the largest Orally Disintegrating Tablet Excipient market with about 30% market share. Americas is follower, accounting for about 27% market share. Key Features: The report on Orally Disintegrating Tablet Excipient market reflects various aspects and provide valuable insights into the industry.

Make this report your own

Have queries/questions regarding a report?

Take advantage of intelligence tailored to your business objective

Manmayi Raval

Manmayi Raval

Research Consultant

Market Drivers and Challenges: Market Drivers- Patient Convenience and Compliance: Compared to conventional oral dosing forms, oral disintegrating tablets provide a convenient and patient-friendly option. They dissolve rapidly in the mouth without the need for water, which facilitates the use of drugs by elderly, pediatric, and dysphagic patients. Because ODTs are easier to administer and have improved patient compliance, demand for them has grown. Growing Geriatric Population: As the world's geriatric population ages, age-related illnesses are becoming more common, and more people require medication. ODTs offer an appropriate choice for senior individuals who could have trouble swallowing or have diminished cognitive function. The need for excipients and orally disintegrating tablet formulations is being driven by the growing elderly population. The market for over the counter (OTC) and nutritional products is growing. Orally disintegrating tablet formulation innovation is driven by the increased demand for over-the-counter pharmaceuticals, dietary supplements, and nutraceutical items. In the OTC and nutraceutical markets, excipients such flavorings, sweeteners, and taste masking agents are essential for improving the palatability and customer acceptance of ODT products. Market Challenges- The formulation of orally disintegrating tablets poses several issues, including but not limited to preserving tablet integrity, mitigating flavour, and guaranteeing API stability throughout the production and storage processes. To ensure the quality and performance of the final product and overcome formulation issues, it is imperative to carefully consider excipient selection, dosage form design, and process optimization.

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Manmayi Raval

Market competition and cost constraints: Excipient producers and formulators face difficulty in developing cost-effective ODT formulations that maintain quality, efficacy, and patient acceptance due to price dynamics, market rivalry, and cost pressures. To remain competitive in the market, businesses must implement strategic pricing plans, provide value-added services, and differentiate themselves through cutting-edge excipient technology. Technological Developments: Super disintegrants and Disintegration Enhancers: Super disintegrants are essential for facilitating quick tablet disintegration and dissolving in the oral cavity. Examples of these are crospovidone, croscarmellose sodium, and sodium starch glycolate. The disintegration kinetics and overall performance of tablets are improved by advancements in formulation design, particle engineering, and super disintegrant technology. Taste Masking and Flavouring Agents: Particularly in paediatric and geriatric populations, taste masking agents, sweeteners, and flavouring agents are used to increase the palatability and consumer acceptance of orally disintegrating tablets. Technological developments in flavour modification, microencapsulation, and taste masking have made it possible to create ODT formulations that taste good and increase patient compliance. Recommendations and Opportunities: Customized Solutions and Patient-Centric Formulations: Opportunities for market differentiation and value creation arise when ODT formulations are tailored to patient demands, preferences, and therapeutic requirements. Patient-centric methods, tailored excipient solutions, and formulation design services improve product acceptance, safety, and efficacy, which promotes market uptake and brand loyalty. Quality Assurance and Regulatory Compliance: Excipient manufacturers need to keep strict quality assurance procedures in place and give regulatory compliance priority. Complying with legal requirements and acquiring required certifications will increase the market acceptability and credibility of excipient goods. Market Forecasts and Future Outlook: The market for oral disintegrating tablet excipients is expected to grow in the future due to factors such as changing pharmaceutical formulations, patient-friendly dosage forms becoming more and more popular, and advances in drug delivery technology. The need for creative excipient solutions for orally disintegrating tablet formulations is anticipated to increase as pharmaceutical companies focus patient-centric methods. This will create chances for technological advancement, market expansion, and strategic collaborations. Market Size and Growth: The research report provide an overview of the current size and growth of the Orally Disintegrating Tablet Excipient market. It may include historical data, market segmentation by Type (e.g., Binders, Glidents), and regional breakdowns. Competitive Landscape: The research report provides analysis of the competitive landscape within the Orally Disintegrating Tablet Excipient market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market. Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Orally Disintegrating Tablet Excipient market. It includes factors influencing customer ' purchasing decisions, preferences for Orally Disintegrating Tablet Excipient product. Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Orally Disintegrating Tablet Excipient market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Orally Disintegrating Tablet Excipient market. The report also evaluates the effectiveness of these policies in driving market growth. Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Orally Disintegrating Tablet Excipient market. Market Segmentation: Orally Disintegrating Tablet Excipient market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. Segmentation by type Binders Glidents Diluents Disintegrants Others Segmentation by application Anti-Psychotics Drug Anti-Epileptics Drug Others Segmentation by region: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries Key Players The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration. BASF JRS Pharma Roquette ABF Ingredients DFE Pharma Evonik Merck KGaA Ashland Meggle Pharma Shin-Etsu Fuji Chemical Industries McePharma (Vivesa holding) Cargill Incorporated Daicel Corporation Anhui Sunhere Pharmaceutical

Table of Contents

  • 1 Scope of the Report
  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered
  • 1.8 Market Estimation Caveats
  • 2 Executive Summary
  • 2.1 World Market Overview
  • 2.1.1 Global Orally Disintegrating Tablet Excipient Annual Sales 2019-2030
  • 2.1.2 World Current & Future Analysis for Orally Disintegrating Tablet Excipient by Geographic Region, 2019, 2023 & 2030
  • 2.1.3 World Current & Future Analysis for Orally Disintegrating Tablet Excipient by Country/Region, 2019, 2023 & 2030
  • 2.2 Orally Disintegrating Tablet Excipient Segment by Type
  • 2.2.1 Binders
  • 2.2.2 Glidents
  • 2.2.3 Diluents
  • 2.2.4 Disintegrants
  • 2.2.5 Others
  • 2.3 Orally Disintegrating Tablet Excipient Sales by Type
  • 2.3.1 Global Orally Disintegrating Tablet Excipient Sales Market Share by Type (2019-2024)
  • 2.3.2 Global Orally Disintegrating Tablet Excipient Revenue and Market Share by Type (2019-2024)
  • 2.3.3 Global Orally Disintegrating Tablet Excipient Sale Price by Type (2019-2024)
  • 2.4 Orally Disintegrating Tablet Excipient Segment by Application
  • 2.4.1 Anti-Psychotics Drug
  • 2.4.2 Anti-Epileptics Drug
  • 2.4.3 Others
  • 2.5 Orally Disintegrating Tablet Excipient Sales by Application
  • 2.5.1 Global Orally Disintegrating Tablet Excipient Sale Market Share by Application (2019-2024)
  • 2.5.2 Global Orally Disintegrating Tablet Excipient Revenue and Market Share by Application (2019-2024)
  • 2.5.3 Global Orally Disintegrating Tablet Excipient Sale Price by Application (2019-2024)
  • 3 Global Orally Disintegrating Tablet Excipient by Company
  • 3.1 Global Orally Disintegrating Tablet Excipient Breakdown Data by Company
  • 3.1.1 Global Orally Disintegrating Tablet Excipient Annual Sales by Company (2019-2024)
  • 3.1.2 Global Orally Disintegrating Tablet Excipient Sales Market Share by Company (2019-2024)
  • 3.2 Global Orally Disintegrating Tablet Excipient Annual Revenue by Company (2019-2024)
  • 3.2.1 Global Orally Disintegrating Tablet Excipient Revenue by Company (2019-2024)
  • 3.2.2 Global Orally Disintegrating Tablet Excipient Revenue Market Share by Company (2019-2024)
  • 3.3 Global Orally Disintegrating Tablet Excipient Sale Price by Company
  • 3.4 Key Manufacturers Orally Disintegrating Tablet Excipient Producing Area Distribution, Sales Area, Product Type
  • 3.4.1 Key Manufacturers Orally Disintegrating Tablet Excipient Product Location Distribution
  • 3.4.2 Players Orally Disintegrating Tablet Excipient Products Offered
  • 3.5 Market Concentration Rate Analysis
  • 3.5.1 Competition Landscape Analysis
  • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
  • 3.6 New Products and Potential Entrants
  • 3.7 Mergers & Acquisitions, Expansion
  • 4 World Historic Review for Orally Disintegrating Tablet Excipient by Geographic Region
  • 4.1 World Historic Orally Disintegrating Tablet Excipient Market Size by Geographic Region (2019-2024)
  • 4.1.1 Global Orally Disintegrating Tablet Excipient Annual Sales by Geographic Region (2019-2024)
  • 4.1.2 Global Orally Disintegrating Tablet Excipient Annual Revenue by Geographic Region (2019-2024)
  • 4.2 World Historic Orally Disintegrating Tablet Excipient Market Size by Country/Region (2019-2024)
  • 4.2.1 Global Orally Disintegrating Tablet Excipient Annual Sales by Country/Region (2019-2024)
  • 4.2.2 Global Orally Disintegrating Tablet Excipient Annual Revenue by Country/Region (2019-2024)
  • 4.3 Americas Orally Disintegrating Tablet Excipient Sales Growth
  • 4.4 APAC Orally Disintegrating Tablet Excipient Sales Growth
  • 4.5 Europe Orally Disintegrating Tablet Excipient Sales Growth
  • 4.6 Middle East & Africa Orally Disintegrating Tablet Excipient Sales Growth
  • 5 Americas
  • 5.1 Americas Orally Disintegrating Tablet Excipient Sales by Country
  • 5.1.1 Americas Orally Disintegrating Tablet Excipient Sales by Country (2019-2024)
  • 5.1.2 Americas Orally Disintegrating Tablet Excipient Revenue by Country (2019-2024)
  • 5.2 Americas Orally Disintegrating Tablet Excipient Sales by Type
  • 5.3 Americas Orally Disintegrating Tablet Excipient Sales by Application
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil
  • 6 APAC
  • 6.1 APAC Orally Disintegrating Tablet Excipient Sales by Region
  • 6.1.1 APAC Orally Disintegrating Tablet Excipient Sales by Region (2019-2024)
  • 6.1.2 APAC Orally Disintegrating Tablet Excipient Revenue by Region (2019-2024)
  • 6.2 APAC Orally Disintegrating Tablet Excipient Sales by Type
  • 6.3 APAC Orally Disintegrating Tablet Excipient Sales by Application
  • 6.4 China
  • 6.5 Japan
  • 6.6 South Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia
  • 6.10 China Taiwan
  • 7 Europe
  • 7.1 Europe Orally Disintegrating Tablet Excipient by Country
  • 7.1.1 Europe Orally Disintegrating Tablet Excipient Sales by Country (2019-2024)
  • 7.1.2 Europe Orally Disintegrating Tablet Excipient Revenue by Country (2019-2024)
  • 7.2 Europe Orally Disintegrating Tablet Excipient Sales by Type
  • 7.3 Europe Orally Disintegrating Tablet Excipient Sales by Application
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia
  • 8 Middle East & Africa
  • 8.1 Middle East & Africa Orally Disintegrating Tablet Excipient by Country
  • 8.1.1 Middle East & Africa Orally Disintegrating Tablet Excipient Sales by Country (2019-2024)
  • 8.1.2 Middle East & Africa Orally Disintegrating Tablet Excipient Revenue by Country (2019-2024)
  • 8.2 Middle East & Africa Orally Disintegrating Tablet Excipient Sales by Type
  • 8.3 Middle East & Africa Orally Disintegrating Tablet Excipient Sales by Application
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends
  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends
  • 10 Manufacturing Cost Structure Analysis
  • 10.1 Raw Material and Suppliers
  • 10.2 Manufacturing Cost Structure Analysis of Orally Disintegrating Tablet Excipient
  • 10.3 Manufacturing Process Analysis of Orally Disintegrating Tablet Excipient
  • 10.4 Industry Chain Structure of Orally Disintegrating Tablet Excipient
  • 11 Marketing, Distributors and Customer
  • 11.1 Sales Channel
  • 11.1.1 Direct Channels
  • 11.1.2 Indirect Channels
  • 11.2 Orally Disintegrating Tablet Excipient Distributors
  • 11.3 Orally Disintegrating Tablet Excipient Customer
  • 12 World Forecast Review for Orally Disintegrating Tablet Excipient by Geographic Region
  • 12.1 Global Orally Disintegrating Tablet Excipient Market Size Forecast by Region
  • 12.1.1 Global Orally Disintegrating Tablet Excipient Forecast by Region (2025-2030)
  • 12.1.2 Global Orally Disintegrating Tablet Excipient Annual Revenue Forecast by Region (2025-2030)
  • 12.2 Americas Forecast by Country
  • 12.3 APAC Forecast by Region
  • 12.4 Europe Forecast by Country
  • 12.5 Middle East & Africa Forecast by Country
  • 12.6 Global Orally Disintegrating Tablet Excipient Forecast by Type
  • 12.7 Global Orally Disintegrating Tablet Excipient Forecast by Application
  • 13 Key Players Analysis
  • 13.1 BASF
  • 13.1.1 BASF Company Information
  • 13.1.2 BASF Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
  • 13.1.3 BASF Orally Disintegrating Tablet Excipient Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.1.4 BASF Main Business Overview
  • 13.1.5 BASF Latest Developments
  • 13.2 JRS Pharma
  • 13.2.1 JRS Pharma Company Information
  • 13.2.2 JRS Pharma Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
  • 13.2.3 JRS Pharma Orally Disintegrating Tablet Excipient Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.2.4 JRS Pharma Main Business Overview
  • 13.2.5 JRS Pharma Latest Developments
  • 13.3 Roquette
  • 13.3.1 Roquette Company Information
  • 13.3.2 Roquette Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
  • 13.3.3 Roquette Orally Disintegrating Tablet Excipient Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.3.4 Roquette Main Business Overview
  • 13.3.5 Roquette Latest Developments
  • 13.4 ABF Ingredients
  • 13.4.1 ABF Ingredients Company Information
  • 13.4.2 ABF Ingredients Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
  • 13.4.3 ABF Ingredients Orally Disintegrating Tablet Excipient Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.4.4 ABF Ingredients Main Business Overview
  • 13.4.5 ABF Ingredients Latest Developments
  • 13.5 DFE Pharma
  • 13.5.1 DFE Pharma Company Information
  • 13.5.2 DFE Pharma Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
  • 13.5.3 DFE Pharma Orally Disintegrating Tablet Excipient Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.5.4 DFE Pharma Main Business Overview
  • 13.5.5 DFE Pharma Latest Developments
  • 13.6 Evonik
  • 13.6.1 Evonik Company Information
  • 13.6.2 Evonik Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
  • 13.6.3 Evonik Orally Disintegrating Tablet Excipient Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.6.4 Evonik Main Business Overview
  • 13.6.5 Evonik Latest Developments
  • 13.7 Merck KGaA
  • 13.7.1 Merck KGaA Company Information
  • 13.7.2 Merck KGaA Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
  • 13.7.3 Merck KGaA Orally Disintegrating Tablet Excipient Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.7.4 Merck KGaA Main Business Overview
  • 13.7.5 Merck KGaA Latest Developments
  • 13.8 Ashland
  • 13.8.1 Ashland Company Information
  • 13.8.2 Ashland Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
  • 13.8.3 Ashland Orally Disintegrating Tablet Excipient Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.8.4 Ashland Main Business Overview
  • 13.8.5 Ashland Latest Developments
  • 13.9 Meggle Pharma
  • 13.9.1 Meggle Pharma Company Information
  • 13.9.2 Meggle Pharma Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
  • 13.9.3 Meggle Pharma Orally Disintegrating Tablet Excipient Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.9.4 Meggle Pharma Main Business Overview
  • 13.9.5 Meggle Pharma Latest Developments
  • 13.10 Shin-Etsu
  • 13.10.1 Shin-Etsu Company Information
  • 13.10.2 Shin-Etsu Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
  • 13.10.3 Shin-Etsu Orally Disintegrating Tablet Excipient Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.10.4 Shin-Etsu Main Business Overview
  • 13.10.5 Shin-Etsu Latest Developments
  • 13.11 Fuji Chemical Industries
  • 13.11.1 Fuji Chemical Industries Company Information
  • 13.11.2 Fuji Chemical Industries Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
  • 13.11.3 Fuji Chemical Industries Orally Disintegrating Tablet Excipient Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.11.4 Fuji Chemical Industries Main Business Overview
  • 13.11.5 Fuji Chemical Industries Latest Developments
  • 13.12 McePharma (Vivesa holding)
  • 13.12.1 McePharma (Vivesa holding) Company Information
  • 13.12.2 McePharma (Vivesa holding) Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
  • 13.12.3 McePharma (Vivesa holding) Orally Disintegrating Tablet Excipient Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.12.4 McePharma (Vivesa holding) Main Business Overview
  • 13.12.5 McePharma (Vivesa holding) Latest Developments
  • 13.13 Cargill Incorporated
  • 13.13.1 Cargill Incorporated Company Information
  • 13.13.2 Cargill Incorporated Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
  • 13.13.3 Cargill Incorporated Orally Disintegrating Tablet Excipient Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.13.4 Cargill Incorporated Main Business Overview
  • 13.13.5 Cargill Incorporated Latest Developments
  • 13.14 Daicel Corporation
  • 13.14.1 Daicel Corporation Company Information
  • 13.14.2 Daicel Corporation Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
  • 13.14.3 Daicel Corporation Orally Disintegrating Tablet Excipient Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.14.4 Daicel Corporation Main Business Overview
  • 13.14.5 Daicel Corporation Latest Developments
  • 13.15 Anhui Sunhere Pharmaceutical
  • 13.15.1 Anhui Sunhere Pharmaceutical Company Information
  • 13.15.2 Anhui Sunhere Pharmaceutical Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
  • 13.15.3 Anhui Sunhere Pharmaceutical Orally Disintegrating Tablet Excipient Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.15.4 Anhui Sunhere Pharmaceutical Main Business Overview
  • 13.15.5 Anhui Sunhere Pharmaceutical Latest Developments
  • 14 Research Findings and Conclusion

List of Tables
Table 1. Orally Disintegrating Tablet Excipient Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Orally Disintegrating Tablet Excipient Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Binders
Table 4. Major Players of Glidents
Table 5. Major Players of Diluents
Table 6. Major Players of Disintegrants
Table 7. Major Players of Others
Table 8. Global Orally Disintegrating Tablet Excipient Sales by Type (2019-2024) & (K MT)
Table 9. Global Orally Disintegrating Tablet Excipient Sales Market Share by Type (2019-2024)
Table 10. Global Orally Disintegrating Tablet Excipient Revenue by Type (2019-2024) & ($ million)
Table 11. Global Orally Disintegrating Tablet Excipient Revenue Market Share by Type (2019-2024)
Table 12. Global Orally Disintegrating Tablet Excipient Sale Price by Type (2019-2024) & (USD/MT)
Table 13. Global Orally Disintegrating Tablet Excipient Sales by Application (2019-2024) & (K MT)
Table 14. Global Orally Disintegrating Tablet Excipient Sales Market Share by Application (2019-2024)
Table 15. Global Orally Disintegrating Tablet Excipient Revenue by Application (2019-2024)
Table 16. Global Orally Disintegrating Tablet Excipient Revenue Market Share by Application (2019-2024)
Table 17. Global Orally Disintegrating Tablet Excipient Sale Price by Application (2019-2024) & (USD/MT)
Table 18. Global Orally Disintegrating Tablet Excipient Sales by Company (2019-2024) & (K MT)
Table 19. Global Orally Disintegrating Tablet Excipient Sales Market Share by Company (2019-2024)
Table 20. Global Orally Disintegrating Tablet Excipient Revenue by Company (2019-2024) ($ Millions)
Table 21. Global Orally Disintegrating Tablet Excipient Revenue Market Share by Company (2019-2024)
Table 22. Global Orally Disintegrating Tablet Excipient Sale Price by Company (2019-2024) & (USD/MT)
Table 23. Key Manufacturers Orally Disintegrating Tablet Excipient Producing Area Distribution and Sales Area
Table 24. Players Orally Disintegrating Tablet Excipient Products Offered
Table 25. Orally Disintegrating Tablet Excipient Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global Orally Disintegrating Tablet Excipient Sales by Geographic Region (2019-2024) & (K MT)
Table 29. Global Orally Disintegrating Tablet Excipient Sales Market Share Geographic Region (2019-2024)
Table 30. Global Orally Disintegrating Tablet Excipient Revenue by Geographic Region (2019-2024) & ($ millions)
Table 31. Global Orally Disintegrating Tablet Excipient Revenue Market Share by Geographic Region (2019-2024)
Table 32. Global Orally Disintegrating Tablet Excipient Sales by Country/Region (2019-2024) & (K MT)
Table 33. Global Orally Disintegrating Tablet Excipient Sales Market Share by Country/Region (2019-2024)
Table 34. Global Orally Disintegrating Tablet Excipient Revenue by Country/Region (2019-2024) & ($ millions)
Table 35. Global Orally Disintegrating Tablet Excipient Revenue Market Share by Country/Region (2019-2024)
Table 36. Americas Orally Disintegrating Tablet Excipient Sales by Country (2019-2024) & (K MT)
Table 37. Americas Orally Disintegrating Tablet Excipient Sales Market Share by Country (2019-2024)
Table 38. Americas Orally Disintegrating Tablet Excipient Revenue by Country (2019-2024) & ($ Millions)
Table 39. Americas Orally Disintegrating Tablet Excipient Revenue Market Share by Country (2019-2024)
Table 40. Americas Orally Disintegrating Tablet Excipient Sales by Type (2019-2024) & (K MT)
Table 41. Americas Orally Disintegrating Tablet Excipient Sales by Application (2019-2024) & (K MT)
Table 42. APAC Orally Disintegrating Tablet Excipient Sales by Region (2019-2024) & (K MT)
Table 43. APAC Orally Disintegrating Tablet Excipient Sales Market Share by Region (2019-2024)
Table 44. APAC Orally Disintegrating Tablet Excipient Revenue by Region (2019-2024) & ($ Millions)
Table 45. APAC Orally Disintegrating Tablet Excipient Revenue Market Share by Region (2019-2024)
Table 46. APAC Orally Disintegrating Tablet Excipient Sales by Type (2019-2024) & (K MT)
Table 47. APAC Orally Disintegrating Tablet Excipient Sales by Application (2019-2024) & (K MT)
Table 48. Europe Orally Disintegrating Tablet Excipient Sales by Country (2019-2024) & (K MT)
Table 49. Europe Orally Disintegrating Tablet Excipient Sales Market Share by Country (2019-2024)
Table 50. Europe Orally Disintegrating Tablet Excipient Revenue by Country (2019-2024) & ($ Millions)
Table 51. Europe Orally Disintegrating Tablet Excipient Revenue Market Share by Country (2019-2024)
Table 52. Europe Orally Disintegrating Tablet Excipient Sales by Type (2019-2024) & (K MT)
Table 53. Europe Orally Disintegrating Tablet Excipient Sales by Application (2019-2024) & (K MT)
Table 54. Middle East & Africa Orally Disintegrating Tablet Excipient Sales by Country (2019-2024) & (K MT)
Table 55. Middle East & Africa Orally Disintegrating Tablet Excipient Sales Market Share by Country (2019-2024)
Table 56. Middle East & Africa Orally Disintegrating Tablet Excipient Revenue by Country (2019-2024) & ($ Millions)
Table 57. Middle East & Africa Orally Disintegrating Tablet Excipient Revenue Market Share by Country (2019-2024)
Table 58. Middle East & Africa Orally Disintegrating Tablet Excipient Sales by Type (2019-2024) & (K MT)
Table 59. Middle East & Africa Orally Disintegrating Tablet Excipient Sales by Application (2019-2024) & (K MT)
Table 60. Key Market Drivers & Growth Opportunities of Orally Disintegrating Tablet Excipient
Table 61. Key Market Challenges & Risks of Orally Disintegrating Tablet Excipient
Table 62. Key Industry Trends of Orally Disintegrating Tablet Excipient
Table 63. Orally Disintegrating Tablet Excipient Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. Orally Disintegrating Tablet Excipient Distributors List
Table 66. Orally Disintegrating Tablet Excipient Customer List
Table 67. Global Orally Disintegrating Tablet Excipient Sales Forecast by Region (2025-2030) & (K MT)
Table 68. Global Orally Disintegrating Tablet Excipient Revenue Forecast by Region (2025-2030) & ($ millions)
Table 69. Americas Orally Disintegrating Tablet Excipient Sales Forecast by Country (2025-2030) & (K MT)
Table 70. Americas Orally Disintegrating Tablet Excipient Revenue Forecast by Country (2025-2030) & ($ millions)
Table 71. APAC Orally Disintegrating Tablet Excipient Sales Forecast by Region (2025-2030) & (K MT)
Table 72. APAC Orally Disintegrating Tablet Excipient Revenue Forecast by Region (2025-2030) & ($ millions)
Table 73. Europe Orally Disintegrating Tablet Excipient Sales Forecast by Country (2025-2030) & (K MT)
Table 74. Europe Orally Disintegrating Tablet Excipient Revenue Forecast by Country (2025-2030) & ($ millions)
Table 75. Middle East & Africa Orally Disintegrating Tablet Excipient Sales Forecast by Country (2025-2030) & (K MT)
Table 76. Middle East & Africa Orally Disintegrating Tablet Excipient Revenue Forecast by Country (2025-2030) & ($ millions)
Table 77. Global Orally Disintegrating Tablet Excipient Sales Forecast by Type (2025-2030) & (K MT)
Table 78. Global Orally Disintegrating Tablet Excipient Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 79. Global Orally Disintegrating Tablet Excipient Sales Forecast by Application (2025-2030) & (K MT)
Table 80. Global Orally Disintegrating Tablet Excipient Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 81. BASF Basic Information, Orally Disintegrating Tablet Excipient Manufacturing Base, Sales Area and Its Competitors
Table 82. BASF Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
Table 83. BASF Orally Disintegrating Tablet Excipient Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 84. BASF Main Business
Table 85. BASF Latest Developments
Table 86. JRS Pharma Basic Information, Orally Disintegrating Tablet Excipient Manufacturing Base, Sales Area and Its Competitors
Table 87. JRS Pharma Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
Table 88. JRS Pharma Orally Disintegrating Tablet Excipient Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 89. JRS Pharma Main Business
Table 90. JRS Pharma Latest Developments
Table 91. Roquette Basic Information, Orally Disintegrating Tablet Excipient Manufacturing Base, Sales Area and Its Competitors
Table 92. Roquette Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
Table 93. Roquette Orally Disintegrating Tablet Excipient Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 94. Roquette Main Business
Table 95. Roquette Latest Developments
Table 96. ABF Ingredients Basic Information, Orally Disintegrating Tablet Excipient Manufacturing Base, Sales Area and Its Competitors
Table 97. ABF Ingredients Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
Table 98. ABF Ingredients Orally Disintegrating Tablet Excipient Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 99. ABF Ingredients Main Business
Table 100. ABF Ingredients Latest Developments
Table 101. DFE Pharma Basic Information, Orally Disintegrating Tablet Excipient Manufacturing Base, Sales Area and Its Competitors
Table 102. DFE Pharma Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
Table 103. DFE Pharma Orally Disintegrating Tablet Excipient Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 104. DFE Pharma Main Business
Table 105. DFE Pharma Latest Developments
Table 106. Evonik Basic Information, Orally Disintegrating Tablet Excipient Manufacturing Base, Sales Area and Its Competitors
Table 107. Evonik Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
Table 108. Evonik Orally Disintegrating Tablet Excipient Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 109. Evonik Main Business
Table 110. Evonik Latest Developments
Table 111. Merck KGaA Basic Information, Orally Disintegrating Tablet Excipient Manufacturing Base, Sales Area and Its Competitors
Table 112. Merck KGaA Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
Table 113. Merck KGaA Orally Disintegrating Tablet Excipient Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 114. Merck KGaA Main Business
Table 115. Merck KGaA Latest Developments
Table 116. Ashland Basic Information, Orally Disintegrating Tablet Excipient Manufacturing Base, Sales Area and Its Competitors
Table 117. Ashland Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
Table 118. Ashland Orally Disintegrating Tablet Excipient Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 119. Ashland Main Business
Table 120. Ashland Latest Developments
Table 121. Meggle Pharma Basic Information, Orally Disintegrating Tablet Excipient Manufacturing Base, Sales Area and Its Competitors
Table 122. Meggle Pharma Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
Table 123. Meggle Pharma Orally Disintegrating Tablet Excipient Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 124. Meggle Pharma Main Business
Table 125. Meggle Pharma Latest Developments
Table 126. Shin-Etsu Basic Information, Orally Disintegrating Tablet Excipient Manufacturing Base, Sales Area and Its Competitors
Table 127. Shin-Etsu Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
Table 128. Shin-Etsu Orally Disintegrating Tablet Excipient Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 129. Shin-Etsu Main Business
Table 130. Shin-Etsu Latest Developments
Table 131. Fuji Chemical Industries Basic Information, Orally Disintegrating Tablet Excipient Manufacturing Base, Sales Area and Its Competitors
Table 132. Fuji Chemical Industries Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
Table 133. Fuji Chemical Industries Orally Disintegrating Tablet Excipient Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 134. Fuji Chemical Industries Main Business
Table 135. Fuji Chemical Industries Latest Developments
Table 136. McePharma (Vivesa holding) Basic Information, Orally Disintegrating Tablet Excipient Manufacturing Base, Sales Area and Its Competitors
Table 137. McePharma (Vivesa holding) Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
Table 138. McePharma (Vivesa holding) Orally Disintegrating Tablet Excipient Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 139. McePharma (Vivesa holding) Main Business
Table 140. McePharma (Vivesa holding) Latest Developments
Table 141. Cargill Incorporated Basic Information, Orally Disintegrating Tablet Excipient Manufacturing Base, Sales Area and Its Competitors
Table 142. Cargill Incorporated Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
Table 143. Cargill Incorporated Orally Disintegrating Tablet Excipient Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 144. Cargill Incorporated Main Business
Table 145. Cargill Incorporated Latest Developments
Table 146. Daicel Corporation Basic Information, Orally Disintegrating Tablet Excipient Manufacturing Base, Sales Area and Its Competitors
Table 147. Daicel Corporation Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
Table 148. Daicel Corporation Orally Disintegrating Tablet Excipient Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 149. Daicel Corporation Main Business
Table 150. Daicel Corporation Latest Developments
Table 151. Anhui Sunhere Pharmaceutical Basic Information, Orally Disintegrating Tablet Excipient Manufacturing Base, Sales Area and Its Competitors
Table 152. Anhui Sunhere Pharmaceutical Orally Disintegrating Tablet Excipient Product Portfolios and Specifications
Table 153. Anhui Sunhere Pharmaceutical Orally Disintegrating Tablet Excipient Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 154. Anhui Sunhere Pharmaceutical Main Business
Table 155. Anhui Sunhere Pharmaceutical Latest Developments

Related Tags

Related Reports

payment cards

Allows one individual to access the purchased report Read More

Allows all employees of an organization to access the purchased report. Internal sharing only Read More

Allows all employees of an organization to access the purchased report. It also permits the use of up to 4 paragraphs or 1 page of the report externally in whitepapers, press releases, and marketing collateral Read More

Buy Now

Safe and Secure SSL Encrypted

Quick Contacts

Want to customize this report?

We offer 10% Free Customization at the time of purchase

Get Free Customization

I'm Available

Rishika Gupta

Rishika Gupta

Team Lead- Business Development

Trusted Partners

NONWOVENS_INDUSTRY
FB
issuewire
Financial_Express
logo_yourstory
FB

Budget constraints? Get in touch with us for special pricing

Request Discount

Order Detail

  • Order Placed (27 July, 2024)
  • Notify To Team (27 July, 2024)
  • Report updation (28 July, 2024)
  • Report Quality Check (28 July, 2024)
  • Report Dispatch (29 July, 2024)

  • paypal
  • icici
  • stripe
  • wire-transfer

  • Email
  • Hard Copy

Research Methodology

An Adaptive Approach to Modern-day Research Needs

Get Methodology

Recently Viewed Products

Logo

Global Orally Disintegrating Tablet Excipient Market Growth 2024-2030

Contact usWe are friendly and approachable, give us a call.

We uses Cookies

We use cookies to ensure you get the best experience on our website.